Oscotec
Highly Engaged Employees
Manufacturing · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bldg. A 700 Daewangpangyo-ro 9F, Seongna...Phone Number
+82 316287666Website
www.oscotec.co.krRevenue
$23.8 MillionStock Symbol
039200Industry
About Oscotec
Oscotec Org Chart
Is Oscotec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Oscotec recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Oscotec
Check if Oscotec has recently received funding, and reach out quickly before it becomes old news!
Click to see if Oscotec had a recent Job posting/layoffs
Check out if Oscotec is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Oscotec has new funding data
Oscotec, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oscotec launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Oscotec is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oscotec is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oscotec.
Oscotec Tech Stack
A closer look at the technologies used by Oscotec
Oscotec News & Media
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly...Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib
With the efficacy comparable to rival drugs, Oscotec plans to advance to the next step, leaving the door open for partnership PANGYO, South Korea, Feb. 24, 2023 /PRNewswire/ -- Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidoplenib (SYK inhibitor) in immune thrombocytopenia (ITP) patients who have failed to respond or relapsed after prior therapy. Cevidoplenib was evaluated in a 61-participant randomized, placebo-controlled trial
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oscotec
Oscotec Inc. specializes in translating scientific research into medical applications, focusing on drug development and innovative healthcare solutions. Their product pipeline includes various drug candidates targeting specific diseases, such as Lazertinib and other inhibitors. Additionally, the company offers medical products like dental bone graf... Read More